potential treatment for Alzheimer’s disease

• Healthcare
• Pharma & Biotech
• United Kingdom

AstraZeneca and Eli Lilly to enrol more than 1,500 patients in 15 countries to their Phase II/III study of oral beta secretase cleaving enzyme (BACE) inhibitor in development as potential treatment for Alzheimer’s disease

Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enrol more than 1,500 patients…